Abstract

The present invention relates to a proteasomal degradation protein complex that comprises an E3 ubiquitin ligase component tethered to an α-synuclein-specific polypeptide binder for degradation of α-synuclein. The present invention also comprises a mechanism of action, composition and related methods for the treatment of neurological disorders including synucleopathies.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 15/86 - Viral vectors

Abstract

An inspection robot for inspecting gastrointestinal tracts or other lumen. The inspection robot is capable of locomotion and comprises: a body, a vibration actuator, and a plurality of resilient legs. The plurality of resilient legs are arranged to protrude outwardly and rearwardly from the body, with respect to a direction of locomotion. Each leg is coupled to the vibration actuator at a proximal end of the leg and the vibration actuator is operable to induce vibrations in a distal end of the leg, which serve, in use, to propel the body in the direction of locomotion by the distal end generating a pushing force against an external surface.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by a mycobacterium, such as tuberculosis.

IPC Classes  ?

• C07D 513/04 - Ortho-condensed systems
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 31/06 - Antibacterial agents for tuberculosis
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

An ultrasound computed tomography apparatus comprises an imaging area configured to accommodate a medium to be imaged; an array of ultrasound elements arranged around the imaging area, the ultrasound elements comprising a transmitter, and a plurality of receivers; respective receiver circuitry for each receiver of the plurality of receivers; and a processing resource configured to perform computed transmission tomography. The transmitter is configured to transmit through the imaging area a sequence of single-tone continuous-wave signals, the sequence of single-tone continuous-wave signals comprising at least one single-tone continuous-wave signal having a first frequency and at least one single-tone continuous-wave signal having a second, different frequency. Each of the plurality of receivers is configured to receive the sequence of single-tone continuous-wave signals that has been transmitted through the imaging area. The respective receiver circuitry for each of the plurality of receivers is configured to mix each received single-tone continuous-wave signal of the sequence of single-tone continuous-wave signals with a respective single-frequency mixer signal having a same frequency as said single-tone continuous-wave signal to obtain a respective in-phase value and a respective quadrature value for said single-tone continuous-wave signal. The processing circuitry is configured to process the obtained in-phase and quadrature values by computed transmission tomography to obtain an image of the imaging area.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications
• A61B 8/14 - Echo-tomography
• A61B 8/13 - Tomography

Abstract

..

IPC Classes  ?

• C07D 495/14 - Ortho-condensed systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 35/00 - Antineoplastic agents
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Goods & Services

Scientific and technological services in the field of vaccine research and development; scientific research and development in the field of vaccines; medical and pharmacological research services in the field of vaccine research and development; research and development of vaccines; vaccine discovery services; providing medical and scientific research information in the field of clinical trials relating to the development of vaccines; information, advice and consultancy in relation to the aforesaid.

Abstract

The present disclosure provides a novel molecule or construct which can mediate or induce protein degradation. The molecules can be provided in the form of constructs and used to mediate the degradation of specific proteins. The molecules comprise an E3 ligase component and a target protein-binding moiety; this ensures the molecules can be tailored to the degradation of a specific proteinaceaous target.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

This invention particularly relates to trifunctional PROTACs of formula I as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to PROTACs including small molecule E3 ubiquitin ligase protein binding ligand compounds which induce preferential degradation of the BRD2 protein within the bromodomain of the BET family of proteins.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Goods & Services

(1) Scientific and technological services in the field of vaccine research and development; scientific research and development in the field of vaccines; medical and pharmacological research services in the field of vaccine research and development; research and development of vaccines; vaccine discovery services; providing medical and scientific research information in the field of clinical trials relating to the development of vaccines; information, advice and consultancy in relation to the aforesaid.

Goods & Services

Scientific and technological services in the field of vaccine research and development; scientific research and development in the field of vaccines; medical and pharmacological research services in the field of vaccine research and development; research and development of vaccines; vaccine discovery services; providing medical and scientific research information in the field of clinical trials relating to the development of vaccines; information, advice and consultancy in relation to the aforesaid.

Abstract

A compound, or a salt or solvate thereof, according to formula I as defined herein and pharmaceutical composition comprising said compound. Compounds of formula I are capable of detecting senescence. As such, these compounds are useful in methods of detecting or imaging senescent cells or extracts thereof or senescence in a subject or a biological sample taken from a subject.

IPC Classes  ?

• C09B 56/16 - Methine- or polymethine-azo dyes
• C09B 56/00 - Azo dyes containing other chromophoric systems
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods of studying eukaryotic cell responses to a perturbation, or of stratifying eukaryotic cells or cell lines into one or more subgroups are described. The methods involve perturbing a library of cells or cell lines in the same manner, and observing how the cells respond to the same perturbation. The observation may be via a high throughput screening method, for example, cell painting; and the perturbation may be, for example, exposure to a therapeutic agent. Methods of studying eukaryotic cell responses to a perturbation, or of stratifying eukaryotic cells or cell lines into one or more subgroups are described. The methods involve perturbing a library of cells or cell lines in the same manner, and observing how the cells respond to the same perturbation. The observation may be via a high throughput screening method, for example, cell painting; and the perturbation may be, for example, exposure to a therapeutic agent. The methods may be used for grouping cells or cell lines that respond similarly to a given therapeutic agent, which may be useful for identifying patient groups and selecting appropriate treatments.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C07K 14/54 - Interleukins [IL]
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/88 - Lyases (4.)

Abstract

The present invention relates to an immunodeficient non-human animal where endogenous drug metabolising enzymes and transcription factors are substantially inactivated. In some aspects of the invention, the animal expresses human drug metabolising enzymes and associated transcription factors. There is also provided related methods of generating the animal of the invention. Additionally, there is provided methods of performing preclinical drug studies using the animal of the invention.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention relates to a method of eluting nucleic acid from a swab. The invention also relates to a kit for eluting nucleic acid from a swab and an elution solution.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma/Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to virus-like particle (VLP) that include one or more viral capsid protein heterodimer(s) each comprising a first monomer encoded by a first amino acid sequence and a second monomer encoded by a second amino acid sequence, and; a binding molecule attached exclusively to either the first monomer or the second monomer, and; wherein the first amino acid sequence and/or the second amino acid sequence comprises at least one mutation which modifies the electrostatic interaction between the first and second monomers to promote association thereof. The present invention also provides processes of producing the VLPs, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/01 - DNA viruses
• C07K 14/08 - RNA viruses
• C07K 14/16 - HIV-1
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suitable for use in treating diseases/conditions which are associated with PTC mutations. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in treating conditions or disorders which are associated with PTC mutations in a subject.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and/or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and/or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

Disclosed are heterobifunctional compounds that can induce the degradation of leucine-rich repeat kinase 2 (LRRK2) and PDE6D. These compounds can engage LRRK2 on one end and bind to an ubiquitin E3 ligase (e.g. cereblon, Von Hippel-Lindau, or Cellular Inhibitor of Apoptosis (cIAP)) on the other end and therefore bring LRRK2 in close proximity to the E3 ligase and induce the ubiquitination and degradation of the LRRK2 protein. Also disclosed are pharmaceutical composition comprising the heterobifunctional compounds and methods of using the compounds to treat LRRK2 and PDE6D- related diseases and disorders.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07K 1/00 - General processes for the preparation of peptides
• A61P 25/16 - Anti-Parkinson drugs
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

Abstract

The present invention relates to compounds according to Formula (I) and their use as CDK8 and/or CDK19 inhibitors.

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 419/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of infectious diseases or in the treatment of diseases caused by Cryptosporidium.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

A computer-implemented method of obtaining cell permeation information for one or more compounds, the method comprising: obtaining molecular structure data representative of molecular structure information for the one or more compounds; generating, using a pre-determined model, permeation data representative of cell permeation information for the one or more compounds based on at least the molecular structure data.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by a mycobacterium, such as tuberculosis.

IPC Classes  ?

• A61P 31/06 - Antibacterial agents for tuberculosis
• C07D 487/04 - Ortho-condensed systems
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Abstract

The present invention relates to a fusion protein that comprises a phosphatase component linked to a polypeptide protein binder that is suitable for inducible targeted dephosphorylation of a phosphorylated proteins of interest. The present invention also comprises methods of regulating protein activity, compositions and methods of treatment of neurodegenerative disorders and cancer.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61P 37/02 - Immunomodulators

Abstract

The present invention relates to a proteasomal degradation protein complex that comprises an E3 ubiquitin ligase component tethered to an ?-synuclein-specific polypeptide binder for degradation of ?-synuclein. The present invention also comprises a mechanism of action, composition and related methods for the treatment of neurological disorders including synucleopathies.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention relates to a proteasomal degradation protein complex that comprises an E3 ubiquitin ligase component tethered to an α-synuclein-specific polypeptide binder for degradation of α-synuclein. The present invention also comprises a mechanism of action, composition and related methods for the treatment of neurological disorders including synucleopathies.

IPC Classes  ?

• A61P 25/16 - Anti-Parkinson drugs
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention concerns a method of degrading target proteins, by forming fusion proteins which comprise hole-modified mutant BET bromodomains conjugated to the target protein and using a degrader compound to initiate protein degradation.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

There is disclosed a stretchable sensor system for measuring deformation of an elastomer, the stretchable sensor system comprising at least one magnet; at least one magnetic sensor, each having a sensor output; and a controller, wherein the at least one magnet is/are fixed to the elastomer at a respective first location or plurality of locations and the at least one magnetic sensor is/are fixed to the elastomer at a respective second location or plurality of locations, such that the or each magnetic sensor is located in magnetic proximity to a respective said magnet, and wherein the controller is operable: to receive sensor data from the sensor output of the or each magnetic sensor; to process the received sensor data in dependence on the first and second locations or plurality of locations to determine a positional relationship between the or each magnet and the respective magnetic sensor; and to compute a deformation of the elastomer in dependence on the determined positional relationship between the or each magnet and the respective magnetic sensor. The present invention has particular application to soft robotics and closed loop control thereof.

IPC Classes  ?

• B25J 19/02 - Sensing devices
• G01L 1/12 - Measuring force or stress, in general by measuring variations in the magnetic properties of materials resulting from the application of stress

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2

Abstract

An inspection robot for inspecting gastrointestinal tracts or other lumen. The inspection robot is capable of locomotion and comprises: a body, a vibration actuator, and a plurality of resilient legs. The plurality of resilient legs are arranged to protrude outwardly and rearwardly from the body, with respect to a direction of locomotion. Each leg is coupled to the vibration actuator at a proximal end of the leg and the vibration actuator is operable to induce vibrations in a distal end of the leg, which serve, in use, to propel the body in the direction of locomotion by the distal end generating a pushing force against an external surface.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2

Abstract

This invention relates to a robot to improve the inspection of a pipe or lumen. More particularly, this invention relates to a soft-pneumatic robot for endoscopy that is suitable for performing colonoscopy procedures. The robot of this invention comprises leading and tailing balloons configured for selective inflation to anchor a portion of the robot within the pipe or lumen and a soft-pneumatic actuator that is located between the leading balloon and the trailing balloon. The soft-pneumatic actuator is operable to extend or contract the robot in a longitudinal direction, in addition to positioning the leading balloon in a 360 degree circumference around the longitudinal direction by pneumatically controlling a fluid within a plurality of chambers within the soft-pneumatic actuator.

IPC Classes  ?

• A61B 1/31 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 34/32 - Surgical robots operating autonomously
• A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments

Abstract

Methods of studying eukaryotic cell responses to a perturbation, or of stratifying eukaryotic cells or cell lines into one or more subgroups are described. The methods involve perturbing a library of cells or cell lines in the same manner, and observing how the cells respond to the same perturbation. The observation may be via a high throughput screening method, for example, cell painting; and the perturbation may be, for example, exposure to a therapeutic agent. The methods may be used for grouping cells or cell lines that respond similarly to a given therapeutic agent, which may be useful for identifying patient groups and selecting appropriate treatments.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Methods of studying eukaryotic cell responses to a perturbation, or of stratifying eukaryotic cells or cell lines into one or more subgroups are described. The methods involve perturbing a library of cells or cell lines in the same manner, and observing how the cells respond to the same perturbation. The observation may be via a high throughput screening method, for example, cell painting; and the perturbation may be, for example, exposure to a therapeutic agent. The methods may be used for grouping cells or cell lines that respond similarly to a given therapeutic agent, which may be useful for identifying patient groups and selecting appropriate treatments.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention is directed to the development of novel photocrosslinking activity based probes (ABPs) and their uses. Specifically, ubiquitin-charged E2 conjugating enzymes are engineered and shown to be effective ABPs of RING ubiquitin E1 and E3 ligases as well as deubiquitination enzymes.

IPC Classes  ?

• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12N 9/10 - Transferases (2.)

Abstract

The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to a method of synthesizing a rhamnose polysaccharide. The invention also relates to a synthetic streptococcal polysaccharide, a streptococcal glycoconjugate, an immunogenic composition or vaccine comprising the streptococcal polysaccharide or glycoconjugate and the polysaccharide, glycoconjugate, immunogenic composition or vaccine for use in raising an immune response in an animal or for use in treating or preventing a disease, condition or infection with a streptococcal aetiology.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A61K 39/09 - Streptococcus
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The invention relates to a method of eluting nucleic acid from a swab. The invention also relates to a kit for eluting nucleic acid from a swab and an elution solution.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to virus-like particles (VLPs) having a high affinity protein attachment system which allows interchangeable decoration with any functional molecule of choice. The present invention further relates to processes of producing the VLPs, including a rapid single cell process, and uses of the VLPs in research, diagnosis and as vaccines for use in prevention/treatment of diseases.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

This invention particularly relates to trifunctional PROTACs of formula I as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to PROTACs including small molecule E3 ubiquitin ligase protein binding ligand compounds which induce preferential degradation of the BRD2 protein within the bromodomain of the BET family of proteins.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems

Goods & Services

Chemicals for use in science; chemical compositions and materials for use in science in the nature of compounds for protein degradation; chemical substances for use in the production of drugs; biological preparations for use in science; chemical products for biotechnological purposes, namely, compounds for protein degradation; diagnostic preparations used for scientific or research use; reagents used for scientific or research use; proteins in raw material form used for scientific or research use Pharmaceuticals, medical and veterinary preparations for protein degradation; diagnostic preparations and materials for veterinary purposes, medical purposes, and scientific use; medicines and biotechnological preparations for medical use for protein degradation; biological and chemical reagents for medical use; drugs for medical purposes for protein degradation; drug delivery agents consisting of compounds that facilitate a wide range of pharmaceuticals Scientific and technological services and research and design relating thereto, namely, research and development of new products for others, design and testing of new product development, scientific research, analysis, and testing in the field of proteins; consultancy relating to research and development in the field of therapeutics; research and development in the field of diagnostics; biotechnological chemical and chemical testing; research and development in the pharmaceutical, chemical and biotechnological fields; research relating to medicines; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services

Abstract

The present disclosure provides a novel molecule or construct which can mediate or induce protein degradation. The molecules can be provided in the form of constructs and used to mediate the degradation of specific proteins. The molecules comprise an E3 ligase component and a target protein-binding moiety; this ensures the molecules can be tailored to the degradation of a specific proteinaceaous target.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

IPC Classes  ?

• C07K 14/52 - CytokinesLymphokinesInterferons

Abstract

The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

IPC Classes  ?

• C07K 14/52 - CytokinesLymphokinesInterferons

Abstract

There is disclosed a stretchable sensor system for measuring deformation of an elastomer, the stretchable sensor system comprising at least one magnet; at least one magnetic sensor, each having a sensor output; and a controller, wherein the at least one magnet is/are fixed to the elastomer at a respective first location or plurality of locations and the at least one magnetic sensor is/are fixed to the elastomer at a respective second location or plurality of locations, such that the or each magnetic sensor is located in magnetic proximity to a respective said magnet, and wherein the controller is operable: to receive sensor data from the sensor output of the or each magnetic sensor; to process the received sensor data in dependence on the first and second locations or plurality of locations to determine a positional relationship between the or each magnet and the respective magnetic sensor; and to compute a deformation of the elastomer in dependence on the determined positional relationship between the or each magnet and the respective magnetic sensor. The present invention has particular application to soft robotics and closed loop control thereof.

IPC Classes  ?

• B25J 13/08 - Controls for manipulators by means of sensing devices, e.g. viewing or touching devices
• B25J 19/02 - Sensing devices
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
• G01L 1/12 - Measuring force or stress, in general by measuring variations in the magnetic properties of materials resulting from the application of stress
• G01L 5/169 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force using magnetic means

Abstract

Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

We disclose a method of determining a concentration of a substance in a sample, the method comprising providing a plurality of first signals, the plurality of first signals being associated with the substance in the sample, providing a plurality of second signals, the plurality of second signals being associated with a reference substance in the sample, the plurality of first and second signals having been obtained by a mass spectrometry method and determining a concentration of the substance in the sample based on at least two first signals of the plurality of first signals and at least two second signals of the plurality of second signals, which correspond to the at least two first signals, wherein at least one of: the at least two first signals and the at least two second signals are correlated with each other.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

IN) received by the second piston (14) to implement tremor cancellation and force and/or provide variable motion scaling.

IPC Classes  ?

• F15B 7/08 - Input unitsMaster units

Abstract

8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

IPC Classes  ?

• C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention is directed to the development of novel photocrosslinking activity based probes (ABPs) and their uses. Specifically, ubiquitin-charged E2 conjugating enzymes are engineered and shown to be effective ABPs of RING ubiquitin E1 and E3 ligases as well as deubiquitination enzymes.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

The present invention is directed to the development of novel photocrosslinking activity based probes (ABPs) and their uses. Specifically, ubiquitin-charged E2 conjugating enzymes are engineered and shown to be effective ABPs of RING ubiquitin E1 and E3 ligases as well as deubiquitination enzymes.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

The present invention relates to methods of detecting illicit substances, or drugs of abuse, as well as devices for use in such methods.

IPC Classes  ?

• C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

The present invention relates to a method for identifying a MYCBP2 modulator. Suitable modulators are identified by modulation of MYCBP2 ubiquitin E3 ligase activity via covalent modification of either of two catalytic cysteines (C4520 and C4572) or by impeding the motion of a newly presented dynamic, so-called, mediator loop region where C4520 resides. The present invention also relates to the use of hydroxy group- containing small molecules and peptides as proxy substrates for measuring MYCBP2 ligase activity and their use in the method of identifying modulators.

IPC Classes  ?

• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase

Abstract

This invention relates to a robot to improve the inspection of a pipe or lumen. More particularly, this invention relates to a soft-pneumatic robot for endoscopy that is suitable for performing colonoscopy procedures. The robot of this invention comprises leading and tailing balloons configured for selective inflation to anchor a portion of the robot within the pipe or lumen and a soft-pneumatic actuator that is located between the leading balloon and the trailing balloon. The soft-pneumatic actuator is operable to extend or contract the robot in a longitudinal direction, in addition to positioning the leading balloon in a 360 degree circumference around the longitudinal direction by pneumatically controlling a fluid within a plurality of chambers within the soft-pneumatic actuator.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 25/10 - Balloon catheters
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/005 - Flexible endoscopes
• A61B 1/008 - Articulations

Abstract

The present invention relates to a method of synthesizing a rhamnose polysaccharide. The invention also relates to a synthetic streptococcal polysaccharide, a streptococcal glycoconjugate, an immunogenic composition or vaccine comprising the streptococcoal polysaccharide or glycoconjugate and the polysaccharide, glycoconjugate, immunogenic composition or vaccine for use in raising an immune response in an animal or for use in treating or preventing a disease, condition or infection with a streptococcal aetiology.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A61K 39/09 - Streptococcus
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to a method of synthesizing a rhamnose polysaccharide. The invention also relates to a synthetic streptococcal polysaccharide, a streptococcal glycoconjugate, an immunogenic composition or vaccine comprising the streptococcoal polysaccharide or glycoconjugate and the polysaccharide, glycoconjugate, immunogenic composition or vaccine for use in raising an immune response in an animal or for use in treating or preventing a disease, condition or infection with a streptococcal aetiology.

IPC Classes  ?

• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A61K 39/09 - Streptococcus
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 35/00 - Antineoplastic agents
• C07D 213/69 - Two or more oxygen atoms

Abstract

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

An actuator (1) is described having a first part (4), a second part (2), and a body portion (3) between the first and second parts, wherein the body portion includes at least one chamber (14) configured to be pressurised and the body portion has a longitudinal axis; and a plurality of cables (6,7,8,9), wherein each of the plurality of cables is arranged in a respective at least partial spiral with respect to the longitudinal axis of the body portion (3); and wherein the plurality of cables are arranged such that the application of a selected force to at least one of the cables causes a desired movement of the first part relative to the second part.

IPC Classes  ?

• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements
• B25J 9/00 - Programme-controlled manipulators
• B25J 15/02 - Gripping heads servo-actuated
• F15B 15/02 - Mechanical layout characterised by the means for converting the movement of the fluid-actuated element into movement of the finally-operated member

Abstract

An actuator includes first and second ends defining an axis there between, and at least four inflatable chambers. Each inflatable chamber is resiliently deformable, elongate, and extends axially between the first and second ends and circumferentially about a central core defined between the ends and by the inflatable chambers. A first pair of the four inflatable chambers is contra rotatory about the core to a second pair of the four inflatable chambers. A pressure change in one or more of the inflatable chambers causes motion of the first end relative to the second end. The actuators can be employed in robots or robotic arms.

IPC Classes  ?

• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements
• F15B 15/02 - Mechanical layout characterised by the means for converting the movement of the fluid-actuated element into movement of the finally-operated member
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
• B25J 19/06 - Safety devices
• F15B 15/06 - Mechanical layout characterised by the means for converting the movement of the fluid-actuated element into movement of the finally-operated member for mechanically converting rectilinear movement into non-rectilinear movement

Abstract

The invention provides for bifunctional molecules comprising an UchL5 binding partner and a target protein binding partner linked via a flexible linker. A bifunctional molecule according to the invention binds to UchL5 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 495/14 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides for bifunctional molecules comprising an Rpn11 binding partner and a target protein binding partner. A bifunctional molecule according to the invention binds to Rpn11 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 495/14 - Ortho-condensed systems
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61P 7/06 - Antianaemics
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides for bifunctional molecules comprising an Usp14 binding partner and a target protein binding partner. A bifunctional molecule according to the invention binds to Usp14 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 495/14 - Ortho-condensed systems

Abstract

A skin sample culture apparatus which has a base frame, with a skin sample receiving surface upon which at least part of the skin sample may be placed and which extends across an area defined by the shape of the frame. A securing member which is releasably connectable to the base frame and a grip which holds the skin sample under tension. The apparatus may include a tensioner to hold the sample under tension and means for introducing a fluid to the upper or lower surface of the sample.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A01N 1/02 - Preservation of living parts
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 1/36 - Embedding or analogous mounting of samples

Abstract

The present invention relates to a method for identifying a MYCBP2 modulator. Suitable modulators are identified by modulation of MYCBP2 ubiquitin E3 ligase activity via covalent modification of either of two catalytic cysteines (C4520 and C4572) or by impeding the motion of a newly presented dynamic, so-called, mediator loop region where C4520 resides. The present invention also relates to the use of hydroxy group- containing small molecules and peptides as proxy substrates for measuring MYCBP2 ligase activity and their use in the method of identifying modulators.

IPC Classes  ?

• C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups

Abstract

The present invention relates to a method for identifying a MYCBP2 modulator. Suitable modulators are identified by modulation of MYCBP2 ubiquitin E3 ligase activity via covalent modification of either of two catalytic cysteines (C4520 and C4572) or by impeding the motion of a newly presented dynamic, so-called, mediator loop region where C4520 resides. The present invention also relates to the use of hydroxy group- containing small molecules and peptides as proxy substrates for measuring MYCBP2 ligase activity and their use in the method of identifying modulators.

IPC Classes  ?

• C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups

Abstract

There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, and to their utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for their preparation thereof, and use in medicine. There is particularly provided novel small molecule E3 ubiquitin ligase protein binding inhibitor compounds based on a fluorohydroxyproline scaffold, to their utility as ligands in synthesizing novel PROTACs, and to synthetic methods therefor.

IPC Classes  ?

• C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 495/14 - Ortho-condensed systems
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings

Abstract

A method of reducing photoelectron yield (PEY) and/or secondary electron yield (SEY) of a ceramic surface comprises applying pulsed laser radiation comprising a series of laser pulses emitted by a laser (4) to the surface of a target (10) to produce a periodic arrangement of structures on the surface of the target (10).

IPC Classes  ?

• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B23K 26/362 - Laser etching
• B23K 26/36 - Removing material
• B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
• B23K 26/04 - Automatically aligning, aiming or focusing the laser beam, e.g. using the back-scattered light
• B23K 26/40 - Removing material taking account of the properties of the material involved
• H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
• H01L 23/525 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body with adaptable interconnections
• B23K 101/36 - Electric or electronic devices
• B23K 103/00 - Materials to be soldered, welded or cut
• B23K 103/14 - Titanium or alloys thereof
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/04 - Steel alloys
• B23K 103/12 - Copper or alloys thereof
• B23K 101/32 - Wires

Abstract

12341233 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO:14) or the sequence SCHLPWASGL (SEQ ID NO:22). The neurological disorder can include those which would benefit from treatment through cognitive enhancement and/or neuroprotection, such as age-associated memory impairment or loss, mild cognitive impairment, and Alzheimer's disease, and can include Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, alcoholic dementia, (DLB) dementia with Lewy bodies, Picks' disease, thalamic dementia, hippocampal sclerosis, Hallervorden-Spatz, multiple system atrophy, tauopathies, subacute aterioscleroitic encephalopathy (Binswanger's disease), amyloid angiopathy, vasculitis, prion diseases, and paraneoplastic syndromes. The invention also includes a pharmaceutical formulation for this method, which can include the peptide in the form of a cyclic peptide or a peptide conjugate.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 14/575 - Hormones
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

An actuator (1) is described having a first part (4), a second part (2), and a body portion (3) between the first and second parts, wherein the body portion includes at least one chamber (14) configured to be pressurised and the body portion has a longitudinal axis; and a plurality of cables (6,7,8,9), wherein each of the plurality of cables is arranged in a respective at least partial spiral with respect to the longitudinal axis of the body portion (3); and wherein the plurality of cables are arranged such that the application of a selected force to at least one of the cables causes a desired movement of the first part relative to the second part.

IPC Classes  ?

• B25J 9/06 - Programme-controlled manipulators characterised by multi-articulated arms
• B25J 9/00 - Programme-controlled manipulators
• B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
• B25J 15/02 - Gripping heads servo-actuated
• B25J 15/12 - Gripping heads having finger members with flexible finger members
• B25J 19/06 - Safety devices

Abstract

A transmission system (10) includes a first piston (12), a second piston (14) and a modulator piston (16). The first piston (12) receives an input force (FIN), the second piston (14) transmits an output force (FOUT), and the modulator piston (16) transmits a modulating force (FACT> which modulates the input force (FIN) received by the second piston (14) to implement tremor cancellation and force and/or provide variable motion scaling.

IPC Classes  ?

• F15B 7/00 - Fluid-pressure actuator systems in which the movement produced is definitely related to the output of a volumetric pumpTelemotors

Abstract

Compounds having the general structure A - L - B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1 B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 38/05 - Dipeptides
• A61P 35/00 - Antineoplastic agents
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

Compounds having the general structure A - L - B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1 B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

IPC Classes  ?

• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61P 35/00 - Antineoplastic agents
• A61K 38/05 - Dipeptides

Abstract

A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosomiasis (HAT), Animal African trypanosomiasis (AAT) and leishmaniasis, particularly visceral leishmaniasis (VL).

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/52 - Purines, e.g. adenine
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Abstract

2, and/or a pulse duration between 200 femtoseconds to 1000 picoseconds.

IPC Classes  ?

• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 103/04 - Steel alloys
• B23K 103/06 - Cast-iron alloys
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/12 - Copper or alloys thereof
• B23K 103/14 - Titanium or alloys thereof

Abstract

A method of injuring or killing an aquatic ectoparasite comprises exposing the aquatic ectoparasite to an aqueous solution comprising hydrogen peroxide and exposing the aquatic ectoparasite to sound waves.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A01K 61/13 - Prevention or treatment of fish diseases
• A61K 33/40 - Peroxides
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• B06B 1/00 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency

Abstract

A method of injuring or killing an aquatic ectoparasite comprises exposing the aquatic ectoparasite to an aqueous solution comprising hydrogen peroxide and exposing the aquatic ectoparasite to sound waves.

IPC Classes  ?

• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• A01K 61/13 - Prevention or treatment of fish diseases

Abstract

2.

IPC Classes  ?

• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B23K 103/04 - Steel alloys
• B23K 103/06 - Cast-iron alloys
• B23K 103/10 - Aluminium or alloys thereof
• B23K 103/12 - Copper or alloys thereof
• B23K 103/14 - Titanium or alloys thereof

Abstract

The present invention relates to a method of diagnosing a bacterial condition in an individual including measuring the levels of NETS in a sample from the individual, in particular measuring the level of sputum NET complexes in the sample. There is also provided a kit for measuring one or more biomarkers associated with NET complexes to predict the likelihood that an individual is suffering from a bacterial condition, and optionally to diagnose the severity of the bacterial condition.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides a compound having the structure: or a salt or ester thereof.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• C07C 255/46 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• C07C 255/47 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

An actuator (1) includes first and second ends (4, 6) defining an axis there between, and at least four inflatable chambers (C1, C2, C3, C4). Each inflatable chamber is resiliently deformable, elongate, and extends axially between the first (4) and second (6) ends and circumferentially about a central core defined between the ends (4, 6) and by the inflatable chambers (C1, C2, C3, C4). A first pair (C1, C3) of the four inflatable chambers is contra rotatory about the core to a second pair (C2, C4) of the four inflatable chambers. A pressure change in one or more of the inflatable chambers causes motion of the first end (4) relative to the second end (6). The actuators (1) can be employed in robots or robotic arms.

IPC Classes  ?

• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
• B25J 19/06 - Safety devices
• F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type
• F15B 15/14 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit of the straight-cylinder type

Abstract

There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, and to their utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for their preparation thereof, and use in medicine. There is particularly provided novel small molecule E3 ubiquitin ligase protein binding inhibitorcompounds based on a fluorohydroxyproline scaffold, to their utility as ligands in synthesizing novel PROTACs, and to synthetic methods therefor.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 495/14 - Ortho-condensed systems
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 35/00 - Antineoplastic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, having utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for the preparation thereof, and use in medicine. There is particularly provided PROTACs which bind to a protein within the bromo- and Extra-terminal (BET) family of proteins, and especially to PROTACs including novel small molecule E3 ubiquitin ligase protein binding ligand compounds which selectively induce degradation of the BRD4 protein within the bromodomain of the BET family of proteins.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/16 - Amides, e.g. hydroxamic acids
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems
• C07D 495/14 - Ortho-condensed systems

Abstract

The compound 3,3,3-trifluoro-N-((1,4-trans)-4-((3-((S)-2-methylmorpholino)-IH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide having the Formula (I) or a salt thereof, its opposite enantiomer, compositions comprising the compound and its use in the treatment or prevention of leishmaniasis, particularly visceral leishmaniasis.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infective agents in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

IPC Classes  ?

• C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

A skin sample culture apparatus is disclosed, which uses a culture medium to maintain the viability of the sample and comprises means for maintaining the sample under tension. In an embodiment the apparatus (171) has a base (173), a securing member (175) and a tensioner cap (177). The skin sample (183) is placed between the base and securing member. Through holes (187) in the securing member are aligned with holes (174) in the base, and screws or other suitable fixings are tightened to secure the skin sample in position. Tension adjustment is provided by the cap, which is positioned on top of the securing member and has a tension adjustment mechanism (179) comprising a screw (195) extending through the cap into the securing member, wherein tightening of the screw increases the tension across the sample.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

An apparatus for reducing parasite infestation of an aquatic animal, for improving the condition, appearance, meat quality or growth rate of an aquatic animal is provided. The apparatus comprises means for providing bubbles in a liquid on or near the surface of the animal or parasite and means for exposing the bubbles to sound waves, wherein the sound waves induce resonance and asymmetric collapse of the bubbles. A method of reducing parasite infestation on an aquatic animal, a method for improving the condition, appearance, meat quality or growth rate of an aquatic animal, and a method for delivery of molecules to an aquatic animal are also provided.

IPC Classes  ?

• A01K 61/13 - Prevention or treatment of fish diseases

Abstract

An apparatus for reducing parasite infestation of an aquatic animal, for improving the condition, appearance, meat quality or growth rate of an aquatic animal is provided. The apparatus comprises means for providing bubbles in a liquid on or near the surface of the animal or parasite and means for exposing the bubbles to sound waves, wherein the sound waves induce resonance and asymmetric collapse of the bubbles. A method of reducing parasite infestation on an aquatic animal, a method for improving the condition, appearance, meat quality or growth rate of an aquatic animal, and a method for delivery of molecules to an aquatic animal are also provided.

IPC Classes  ?

• A01K 61/13 - Prevention or treatment of fish diseases

Abstract

An apparatus for high throughput screening which has a base with channels for receiving a reagent. The channels are spaced across the surface of the base and have one or more walls which extend through the base from a first base surface to a second base surface. A compression member containing a plurality of openings which extend through the compression member and which are positioned across the surface of the compression member, one or more o-' said openings being positioned for alignment with a corresponding channel in the base. A grip for removably securing the compression member to the base such that when a compressible sheet s positioned across the channel between the base and the compression member and fixed by the grip, parts of the compressible sheet are compressed between the base and the compression member to form a seal between the base and the compression member such that and the compressible sheet and walls of the base form one or more wels for containing the reagent.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A method for improving the ex vivo viability of a skin tissue type by mounting samples (27) of the skin tissue type in a skin sample holder (23), applying separate tensions to at least some of the samples and measuring the ability of at least some of the skin tissue samples to maintain live skin characteristics, such as to determine one or more value of skin tension which improve the ex vivo viability of the skin sample type. Tension may be measured using a force meter. The viability may be determined by wounding the skin, e.g. using a laser source, and measuring keratin 17 expression. Cellular viability and/or metabolic activity may also be determined.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to the use of c-Src inhibitors for the mitigation of side-effects associated with opioid analgesia and in particular for the mitigation of opioid tolerance in human and veterinary medicine.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present invention relates to assays for detecting whether or not an animal is or has been infected with Trypanosoma vivax. In addition the invention relates to specific antigens for use in the assays of the invention, as well a specific types of assays and assay devices which employ said specific antigens.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure provides assay methods for identifying agents which modulate binding between DHHC-PAT molecules and their protein binding partners, in particular those binding partners that bind the N- or C-terminal DHHC-PAT tail portion. Further the disclosure provides methods and uses which exploit certain DHHC-PAT/protein binding modulators with the aim of modulating downstream S-acylation (including palmitoylation) events. The disclosure also relates to uses of such modulator molecules and methods and uses for treating diseases and/or conditions associated with protein palmitoylation.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/00 - Medicinal preparations containing organic active ingredients